Precision microbiota therapy for IBD: premise and promise
Inflammatory Bowel Disease (IBD) is a spectrum of chronic inflammatory diseases of the intestine that includes subtypes of ulcerative colitis (UC) and Crohn’s Disease (CD) and currently has no cure. While IBD results from a complex interplay between genetic, environmental, and immunological factors,...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2025.2489067 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850153289763520512 |
|---|---|
| author | Manabu Nagayama Lasha Gogokhia Randy S. Longman |
| author_facet | Manabu Nagayama Lasha Gogokhia Randy S. Longman |
| author_sort | Manabu Nagayama |
| collection | DOAJ |
| description | Inflammatory Bowel Disease (IBD) is a spectrum of chronic inflammatory diseases of the intestine that includes subtypes of ulcerative colitis (UC) and Crohn’s Disease (CD) and currently has no cure. While IBD results from a complex interplay between genetic, environmental, and immunological factors, sequencing advances over the last 10–15 years revealed signature changes in gut microbiota that contribute to the pathogenesis of IBD. These findings highlight IBD as a disease target for microbiome-based therapies, with the potential to treat the underlying microbial pathogenesis and provide adjuvant therapy to the emerging spectrum of advanced therapies for IBD. Building on the success of fecal microbiota transplantation (FMT) for Clostridioides difficile infection, therapies targeting gut microbiota have emerged as promising approaches for treating IBD; however, unique aspects of IBD pathogenesis highlight the need for more precision in the approach to microbiome therapeutics that leverage aspects of recipient and donor selection, diet and xenobiotics, and strain-specific interactions to enhance the efficacy and safety of IBD therapy. This review focuses on both pre-clinical and clinical studies that support the premise for microbial therapeutics for IBD and aims to provide a framework for the development of precision microbiome therapeutics to optimize clinical outcomes for patients with IBD. |
| format | Article |
| id | doaj-art-e84e08adc4444b488c1bc6a1145b8b7a |
| institution | OA Journals |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-e84e08adc4444b488c1bc6a1145b8b7a2025-08-20T02:25:45ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2025.2489067Precision microbiota therapy for IBD: premise and promiseManabu Nagayama0Lasha Gogokhia1Randy S. Longman2Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, New York, NY, USAJill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USAJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, New York, NY, USAInflammatory Bowel Disease (IBD) is a spectrum of chronic inflammatory diseases of the intestine that includes subtypes of ulcerative colitis (UC) and Crohn’s Disease (CD) and currently has no cure. While IBD results from a complex interplay between genetic, environmental, and immunological factors, sequencing advances over the last 10–15 years revealed signature changes in gut microbiota that contribute to the pathogenesis of IBD. These findings highlight IBD as a disease target for microbiome-based therapies, with the potential to treat the underlying microbial pathogenesis and provide adjuvant therapy to the emerging spectrum of advanced therapies for IBD. Building on the success of fecal microbiota transplantation (FMT) for Clostridioides difficile infection, therapies targeting gut microbiota have emerged as promising approaches for treating IBD; however, unique aspects of IBD pathogenesis highlight the need for more precision in the approach to microbiome therapeutics that leverage aspects of recipient and donor selection, diet and xenobiotics, and strain-specific interactions to enhance the efficacy and safety of IBD therapy. This review focuses on both pre-clinical and clinical studies that support the premise for microbial therapeutics for IBD and aims to provide a framework for the development of precision microbiome therapeutics to optimize clinical outcomes for patients with IBD.https://www.tandfonline.com/doi/10.1080/19490976.2025.2489067Inflammatory bowel diseaseCrohn’s diseaseulcerative colitisprecision microbiome therapeutics |
| spellingShingle | Manabu Nagayama Lasha Gogokhia Randy S. Longman Precision microbiota therapy for IBD: premise and promise Gut Microbes Inflammatory bowel disease Crohn’s disease ulcerative colitis precision microbiome therapeutics |
| title | Precision microbiota therapy for IBD: premise and promise |
| title_full | Precision microbiota therapy for IBD: premise and promise |
| title_fullStr | Precision microbiota therapy for IBD: premise and promise |
| title_full_unstemmed | Precision microbiota therapy for IBD: premise and promise |
| title_short | Precision microbiota therapy for IBD: premise and promise |
| title_sort | precision microbiota therapy for ibd premise and promise |
| topic | Inflammatory bowel disease Crohn’s disease ulcerative colitis precision microbiome therapeutics |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2025.2489067 |
| work_keys_str_mv | AT manabunagayama precisionmicrobiotatherapyforibdpremiseandpromise AT lashagogokhia precisionmicrobiotatherapyforibdpremiseandpromise AT randyslongman precisionmicrobiotatherapyforibdpremiseandpromise |